Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Melanoma × infigratinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 2 Acrocephalosyndactylia 2 Urinary Bladder Neoplasms 1 Upper Tract Urothelial Carcinomas 1 Tumor With Alterations of the FGF-R 1 Melanoma 1 Lung Neoplasms 1 Hematologic Neoplasms 1 Glioblastoma 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Breast Neoplasms 1

Interventions

pembrolizumab 146 Nivolumab 98 Ipilimumab 82 Dacarbazine 40 trametinib 34 dabrafenib 30 Vemurafenib 28 atezolizumab 21 binimetinib 19 Temozolomide 19 cemiplimab 16 Paclitaxel 15 cobimetinib 14 spartalizumab 13 encorafenib 12 Cisplatin 12 Carboplatin 12 Cyclophosphamide 10 talimogene laherparepvec 9 lenvatinib 9 durvalumab 9 Docetaxel 9 tremelimumab 8 relatlimab 8 Gemcitabine 8 Drug Therapy 8 Bevacizumab 8 Pemetrexed 7 Albumin-Bound Paclitaxel 7 130-nm albumin-bound paclitaxel 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02159066 2024-03-05

LOGIC-2

Pfizer

Phase 2 Completed

158 enrolled 40 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡